Neopterin adjuvant and vaccine containing neopterin adjuvant

A neopterin and vaccine technology, applied in the field of immunology, can solve the problems of few types of vaccine adjuvants, toxic and side effects, and achieve the effects of excellent immune effect, small toxic and side effects, and enhancement of humoral immune response

Active Publication Date: 2014-09-24
INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In order to solve the problems of few kinds of adjuvants in existing vaccines, toxic and side effects, etc., the present invention provides a safe, effective, stable and economical neopterin adjuvant, and also provides a vaccine containing neopterin adjuvant

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Neopterin adjuvant and vaccine containing neopterin adjuvant
  • Neopterin adjuvant and vaccine containing neopterin adjuvant
  • Neopterin adjuvant and vaccine containing neopterin adjuvant

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] The dosage of the neopterin adjuvant provided in this example is 0.5 μg.

[0020] The hepatitis A vaccine containing neopterin adjuvant provided in this example is as follows: 0.5 μg of neopterin adjuvant is added to each single portion of HAV antigen (that is, a single injection dose for clinical use), and then physiological saline is added to 200 μL , mixed uniformly according to routine, to obtain the hepatitis A vaccine containing neopterin adjuvant, wherein, neopterin is a commercially available product, purchased from SIGMA company, HAV antigen is a commercially available antigen titer of 18EU HAV antigen solution of 512EU / ml , purchased from Institute of Medical Biology, Peking Union Medical College, Chinese Academy of Medical Sciences.

[0021] The immune test and effect of the hepatitis A vaccine that the present embodiment 1 gained contains the neopterin adjuvant are as follows:

[0022] A. Immunity

[0023] The 6-8 week-old, 18-22g clean-grade ICR mice were...

Embodiment 2

[0038] The dosage of the neopterin adjuvant provided in this example is 0.8 μg.

[0039] Add 0.8 μg of neopterin adjuvant to each single portion of HAV antigen (that is, a single injection dose used in clinical practice), add physiological saline to 200 μL, and mix until uniformly mixed according to routine, to obtain a neopterin adjuvant containing Hepatitis A vaccine, wherein, neopterin, HAV antigen are with embodiment 1;

[0040] The preparation of other groups is the same as in Example 1.

[0041] The immune test of the hepatitis A vaccine containing the neopterin adjuvant obtained in Example 2 is the same as in Example 1, and the results are shown in Table 2.

[0042] Table 2 shows the serum anti-HAV IgG antibody levels of mice in each experimental group within 16 weeks after using the adjuvant provided in Example 2.

[0043] Table 2

[0044]

[0045] Through data analysis, it can be seen that from the 4th week after immunization, all experimental groups except the ...

Embodiment 3

[0047] The dosage of the neopterin adjuvant provided in this example is 1 μg.

[0048] Add 1 μg of neopterin adjuvant to each single portion of HAV antigen (that is, the single injection dose used in clinical practice), add physiological saline to 200 μL, and mix until uniformly mixed according to routine to obtain hepatitis A containing neopterin adjuvant Vaccine, wherein, neopterin, HAV antigen are the same as embodiment 1;

[0049] The preparation of other groups is the same as in Example 1.

[0050] The immune test of the hepatitis A vaccine containing the neopterin adjuvant obtained in Example 3 is the same as in Example 1, and the effects are shown in Table 3.

[0051] Table 3 shows the serum anti-HAV IgG antibody levels of mice in each experimental group within 16 weeks after using the adjuvant provided in Example 3.

[0052] table 3

[0053]

[0054] Through data analysis, it can be seen that from the 4th week after immunization, all experimental groups except the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a neopterin adjuvant and a vaccine containing the neopterin adjuvant, and belongs to the technical field of immunology. According to the vaccine containing the neopterin adjuvant, each single vaccine contains 0.5-1 microgram of the neopterin adjuvant. The neopterin adjuvant belongs to an endogenous substance in the human body, is small in toxic and side effects, is safe and reliable when used in an immunizing dose range, and can effectively induce antigenic specificity humoral immune responses, and the induced humoral immune response effect is better than that of a group without adjuvants and similar to that of a group with an aluminum adjuvant. Raw materials of the neopterin adjuvant are easy to obtain, the neopterin adjuvant is a commercially available product and low in cost and can be added to multiple traditional vaccines and genetic engineering vaccines to be used as a vaccine adjuvant.

Description

technical field [0001] The invention belongs to the technical field of immunology, and in particular relates to a neopterin adjuvant and a vaccine containing the adjuvant. Background technique [0002] With the rapid development of molecular biology theory and technology, the research on genetic engineering vaccines also develops rapidly. New genetic engineering vaccines emerge in an endless stream. Such vaccines have the characteristics of high purity and strong specificity. Relatively weaker than natural antigens, it is difficult to generate an efficient immune response. Therefore, research and development of new adjuvants to enhance the immunogenicity of new vaccines is an important topic. [0003] Aluminum salt adjuvants are the adjuvants with the longest history in human vaccines. Practice has proved that aluminum salt adjuvants are safe and effective, but due to their disadvantages such as allergies and degenerative neuropathy induction, there is an urgent need to de...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61P37/04
Inventor 王海漩胡云章胡凝珠
Owner INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap